Articles
7,857 Articles
DoubleBlind Mag
/
Mar 20, 2025
We’ve All Been Duped By Blue Lotus Flower
We've All Been Duped By Blue Lotus Flower PLUS, a Q&A with a leading researcher studying the intersection of psychedelics and meditation Mary Carreon // Senior Editor 20 Mar Good morning and welcome to another edition of The Drop In, DoubleBlind’s newsletter delivering independent...
LSD
Psychedelics
Psychedelic Invest
/
Mar 20, 2025
Clearmind Medicine Announces Publication of Patent for Cocaine Addiction Psychedelic Combination Treatment in South Korea
Vancouver, Canada, March 10, 2025 — Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the “Company”), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today...
Psychedelic Invest
/
Mar 20, 2025
Polyrizon Signs Non– Binding LOI to Expand its Innovative Intranasal Drug Delivery Platform for Psychedelic-Based Treatments
Raanana, Israel, March 14, 2025 (GLOBE NEWSWIRE) — Polyrizon Ltd. (Nasdaq: PLRZ) (the “Company” or “Polyrizon”), a development stage biotech company specializing in the development of innovative intranasal hydrogels, announced today that it has signed a non-binding Letter of Intent...
Psychedelic Invest
/
Mar 20, 2025
MindMed Appoints Matt Wiley as Chief Commercial Officer
NEW YORK–(BUSINESS WIRE)– Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the “Company” or “MindMed”), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the appointment of Matt Wiley as its Chief Commercial...
Psychedelic Invest
/
Mar 20, 2025
Optimi Health Provides Corporate Update
Vancouver, British Columbia–(Newsfile Corp. – March 12, 2025) – Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) (“Optimi” or the “Company“), a GMP-compliant, Health Canada-licensed manufacturer specializing in botanical psilocybin and MDMA, is pleased to provide the following...
Psilocybin
MDMA
Psychedelic Invest
/
Mar 20, 2025
Filament Health Announces Positive Data From Phase 2 Study of PEX010 in Patients With Alcohol Use Disorder
VANCOUVER, BC, March 17, 2025 /CNW/ – Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) (“Filament” or the “Company“), a clinical‐stage natural psychedelic drug development company, today announced positive data from an open-label phase 2 clinical trial studying the effects...
Psychedelic Invest
/
Mar 20, 2025
PharmAla Signs Duchefa Farma as Exclusive Distributor in Netherlands
TORONTO, March 10, 2025 (GLOBE NEWSWIRE) — PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the research, development, and manufacturing of novel MDXX class molecules (including its LaNeo™ MDMA), is excited to...
MDMA
Psychedelic Invest
/
Mar 20, 2025
Neural Therapeutics Commences Trading, Provides Update on Growth Initiatives and Engages Investor Relations Consultants
Toronto, Ontario–(Newsfile Corp. – March 17, 2025) – Neural Therapeutics Inc. (CSE: NURL) (“Neural” or the “Company”), an ethnobotanical drug discovery company dedicated to developing therapeutic drugs for mental illnesses related to substance use disorders, is pleased to announce...
Psychedelic Invest
/
Mar 20, 2025
Psyched Wellness Provides Comprehensive Investor Update
Toronto, Ontario–(Newsfile Corp. – March 14, 2025) – Psyched Wellness Ltd. (CSE: PSYC) (OTCQB: PSYCF) (FSE: 5U9) (the “Company” or “Psyched“), a life sciences company focused on the production and distribution of health and wellness products derived from the Amanita Muscaria mushroom,...
Psychedelic Invest
/
Mar 20, 2025
atai Life Sciences Announces First Patient Dosed in Elumina, the Phase 2 Clinical Trial of VLS-01 for Treatment-Resistant Depression
NEW YORK and BERLIN, March 11, 2025 (GLOBE NEWSWIRE) — atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced that the first patient has been dosed in the Phase 2...
DoubleBlind Mag
/
Mar 19, 2025
Indigenous Nations Issue Urgent Call to Protect Ayahuasca
Indigenous Nations Issue Urgent Call to Protect Ayahuasca The psychedelic renaissance has a dark side — one that Indigenous nations are no longer willing to accept. Mattha Busby 19 Mar Your weekly dose of psychedelic insights and news Indigenous Nations Demand an End to Ayahuasca...
Ayahuasca
Psychedelics Today
/
Mar 18, 2025
Natural Medicine Alaska
In this powerful episode of Psychedelics Today, we sit down with the team behind Natural Medicine Alaska to discuss their groundbreaking efforts to bring psychedelic reform to the state. With some of the highest rates of depression, suicide, and substance use disorders in the nation, Alaska stands...
Psychedelics
DoubleBlind Mag
/
Mar 17, 2025
Here’s Why Psychedelics Actually Enhances Meditation
Here’s Why Psychedelics Actually Enhances Meditation PLUS, synthesizing LSD, the human and environmental toll of iboga, and so much more Mary Carreon // Senior Editor 17 Mar Good morning and welcome to another edition of The Drop In, DoubleBlind’s newsletter delivering independent...
LSD
Psychedelics
Psilocybin Alpha
/
Mar 17, 2025
Pα+ Psychedelic Bulletin #191: Psychedelics at SXSW; Swiss Study Finds No Impact of Psilocybin on Alcohol Use Disorder
Austin’s South by Southwest (SXSW) festival was founded in 1987, just a year after Rick Doblin formed the Multidisciplinary Association for Psychedelic Studies (MAPS). It started as a music festival, with 700 registrants on its first day. Today, the event—which includes a film festival,...
Psilocybin
Psychedelics
DoubleBlind Mag
/
Mar 16, 2025
Meet the woman living every day in psychedelic synesthesia
Meet the woman living every day in psychedelic synesthesia Penny Vieregge has been an Esalen insider, a psychedelic trip-sitter, a gospel-singing EMT, and a poet who never picks up a pen. At 95, she’s still spinning magic in Big Sur. Noelle Armstrong 16 Mar Bringing back the stories you...
DoubleBlind Mag
/
Mar 14, 2025
How to Get Your Parents Curious About Taking Mushrooms
How to Get Your Parents Curious About Taking Mushrooms Think your parent could benefit from psilocybin? Here’s how to talk to them—straight from those who’ve done it successfully. Michele Koh Morollo 14 Mar Deep dives and investigations you won't find anywhere else How to...
DoubleBlind Mag
/
Mar 13, 2025
Sorry, L.A. Times, But Cacao Isn’t Ayahuasca
Sorry, L.A. Times, But Cacao Isn’t Ayahuasca PLUS how to stay connected to plant medicine after ceremony, how to work with Kanna, and “Anonymous Mazatec Curanderas” Mary Carreon // Senior Editor 13 Mar Welcome back to The Drop In, DoubleBlind’s newsletter serving up news, culture,...
MDMA
Ayahuasca
DoubleBlind Mag
/
Mar 12, 2025
Why Don’t Psychedelic Retreats Have a Code of Conduct?
Why Don’t Psychedelic Retreats Have a Code of Conduct? Without ethical guidelines, psychedelic spaces risk harm. Rick Doblin and Jules Evans explore whether a code of conduct could change that. Jack Gorsline 12 Mar Your weekly dose of psychedelic insights and news Would Psychedelic...
Psychedelic Invest
/
Mar 11, 2025
Psyence Biomed Names Albert P. Garcia-Romeu, Ph.D. as Chair of its Newly Created Scientific Advisory Board
About Psyence Biomed:Psyence Biomedical Ltd. (Nasdaq: PBM) is one of the world’s few vertically integrated biopharmas with a focus on psychedelic-based pharmaceutical therapeutics. The first life science biotechnology company developing nature-derived (non-synthetic) psilocybin-based psychedelic...
Psychedelic Invest
/
Mar 11, 2025
PharmAla to supply STRONG STAR at UT Health San Antonio, with novel dosage form of LaNeo™ MDMA
TORONTO, Feb. 27, 2025 (GLOBE NEWSWIRE) — PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the research, development, and manufacturing of LaNeo™ MDMA and novel derivatives of MDMA (MDXX class molecules), is proud to...
MDMA
Psychedelics Today
/
Mar 11, 2025
Erica Siegal LCSW – NEST and SHINE Collective
Joe Moore sits down with Erica Siegal, founder of Nest Harm Reduction and Shine Collective, for a deep conversation on psychedelic harm reduction, ethical facilitation, and the evolving psychedelic landscape. Erica shares her journey from the Grateful Dead lot scene to festival harm reduction,...
Psychedelic Invest
/
Mar 11, 2025
Revive Therapeutics Announces LOI to Acquire DiagnaMed’s Molecular Hydrogen Program
TORONTO, March 03, 2025 (GLOBE NEWSWIRE) — Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for infectious diseases, rare disorders, and medical...
Psychedelic Invest
/
Mar 11, 2025
Enveric Biosciences CEO Issues Letter to Shareholders
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders, today announced...
Psychedelic Invest
/
Mar 11, 2025
Algernon NeuroScience Engages Netcapital Securities for Planned Regulation A Financing
VANCOUVER, British Columbia, March 06, 2025 (GLOBE NEWSWIRE) — Algernon Pharmaceuticals Inc. (the “Company” or “AGN Pharma”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian clinical stage pharmaceutical development company, is pleased to announce that its wholly owned subsidiary...
DMT
Psychedelic Invest
/
Mar 11, 2025
Netcapital to Host Planned Reg A Offering by Algernon NeuroScience
BOSTON, MA, March 07, 2025 (GLOBE NEWSWIRE) — Netcapital Inc. (NASDAQ: NCPL, NCPLW), a digital private capital markets ecosystem, today announced that its subsidiary, Netcapital Securities Inc. (“Netcapital Securities”), a FINRA-registered broker-dealer, has been engaged by Algernon...
DMT
Psychedelic Invest
/
Mar 11, 2025
PharmAla Completes Shipment of LaNeo™ MDMA to UCLA for Schizophrenia Study
TORONTO, March 03, 2025 (GLOBE NEWSWIRE) — PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the research, development, and manufacturing of novel MDXX class molecules (including its LaNeo™ MDMA), is pleased to...
MDMA
Psychedelic Invest
/
Mar 11, 2025
Numinus Wellness Inc. Announces CFO Transition
VANCOUVER, BC, Feb. 18, 2025 /PRNewswire/ – Numinus Wellness Inc. (“Numinus” or the “Company”) (TSX: NUMI) (OTCQX: NUMIF) (FSE: LR23), a mental healthcare company advancing traditional and innovative behavioral health treatments including safe, evidence-based psychedelic-assisted...
Psychedelic Invest
/
Mar 11, 2025
Psyence Group’s NASDAQ-Listed Associate, Psyence Biomedical, names Albert P. Garcia-Romeu, Ph.D. as Chair of its Newly Created Scientific Advisory Board
TORONTO, March 10, 2025 (GLOBE NEWSWIRE) — Psyence Group Inc (“Psyence Group” or the “Company“) (CSE: PSYG) is pleased that its NASDAQ-listed associate, Psyence Biomedical Ltd (NASDAQ: PBM) (“PBM” or “Psyence Biomed“), has announced that it will work closely with Albert P....
Psychedelics
Psychedelic Invest
/
Mar 11, 2025
MindMed Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Updates
NEW YORK–(BUSINESS WIRE)– Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the “Company” or “MindMed”), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced its fourth quarter and full year 2024 financial...
MDMA
DoubleBlind Mag
/
Mar 10, 2025
Is Elon Musk’s ketamine habit a problem for all of us?
Is Elon Musk’s ketamine habit a problem for all of us? PLUS, Meet the people fighting for psychedelic diversity, equity, and inclusion Mary Carreon // Senior Editor 10 Mar Welcome back to The Drop In, DoubleBlind’s newsletter serving up news, culture, and independent journalism about...
Ketamine
Psychedelics
Psychedelics Today
/
Mar 10, 2025
LIVESTREAM: Alaska Natural Medicine
This livestream features David and Gina from Natural Medicine Alaska (NMA). They are part of a team running a project to work towards a psilocybin focused regulated access program in Alaska. We’ll discuss the project’s aims and their path to get there for an hour and will have time to have...
DoubleBlind Mag
/
Mar 09, 2025
Maria Sabina’s Unteachable Gift
Maria Sabina's Unteachable Gift María Sabina wasn’t just a curandera—she was a visionary poet, a musician, and an icon whose talents couldn’t be taught, bought, or replicated. Bett Williams 09 Mar SUPPORTING PARTNER Bringing back the stories you love—no paywall, just joy. ...
Psychedelics
Psychedelic Invest
/
Mar 08, 2025
atai Life Sciences Announces Completion of Enrollment in Phase 2b Clinical Trial Evaluating BPL-003 for Treatment-Resistant Depression
NEW YORK and BERLIN, March 05, 2025 (GLOBE NEWSWIRE) — atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced the completion of patient enrollment in the eight-week,...
DoubleBlind Mag
/
Mar 07, 2025
Inside the Billionaire Takeover of Lykos—and Rick Doblin’s Comeback
Inside the Billionaire Takeover of Lykos—and Rick Doblin’s Comeback As MDMA therapy hangs in the balance, a high-stakes power shift is underway. But will it bring real change or just new faces at the top? Mattha Busby 07 Mar Deep dives and investigations you won't find anywhere else ...
MDMA
Psilocybin Alpha
/
Mar 06, 2025
Pα+ Psychedelic Bulletin #190: ‘Europe’s Most Feared Investor’ Teams Up with Musk Associate to Fund Lykos Therapeutics
In January, we reported on billionaire investor Antonio Gracias’ bid to take control of embattled MDMA drug developer Lykos Therapeutics. Now, Gracias appears to be teaming up with an unlikely co-investor. Psychedelic Alpha understands that the Musk associate and DOGE advisor is joined by an even...
MDMA
DoubleBlind Mag
/
Mar 06, 2025
Did Oprah Just Mainstream Psychedelics?
Did Oprah Just Mainstream Psychedelics? Plus, all the tea on Amazonian snuff, destigmatizing coca, and so much more. Mary Carreon // Senior Editor 06 Mar Welcome back to The Drop In, DoubleBlind’s newsletter serving up news, culture, and independent journalism about psychedelics straight...
MDMA
Ketamine